How much funding has Degron Therapeutics raised?

Degron Therapeutics has raised $62.0M in total funding, most recently a Extension Round.

Who are Degron Therapeutics's investors?

Degron Therapeutics's investors include Lapam Capital, Med-Fine Capital, DYEE Capital, Baidu Ventures, Cowin Ventures, YuanBio Venture Capital.

When was Degron Therapeutics founded?

Degron Therapeutics was founded in 2021.

Where is Degron Therapeutics headquartered?

Degron Therapeutics is headquartered in San Diego, California, United States.

What industry is Degron Therapeutics in?

Degron Therapeutics operates in Biotech.

How many employees does Degron Therapeutics have?

Degron Therapeutics has 51-200 employees.

Degron Therapeutics

Global leader in molecular glue degrader medicines

San Diego, United States · Founded 2021 · $62.0M raised

Biotech

Headquarters: San Diego, California
Employees: 51–200
Founded: 2021
Business Model: B2B

Website: degronsci.com
Total Funding: $62.0M
Last Round: $40.0M Extension RoundMay 2026
Rounds: 2

About

Degron Therapeutics is a clinical-stage biotech developing molecular glue degrader drugs targeting previously undruggable proteins in oncology, inflammation, and metabolic disease. Founded in 2021, the company has advanced its lead asset DEG6498, a first-in-class HuR-targeting MGD, into Phase 1 clinical trials. Headquartered in San Diego with operations in Shanghai.

Summary

Degron Therapeutics is a Biotech company based in San Diego, United States, founded in 2021. It has raised $62.0M in total across 2 rounds, most recently a $40.0M Extension Round round in May 2026. Investors include Lapam Capital, Med-Fine Capital and DYEE Capital.